Artritis idiopática juvenil

Esta enfermedad es un tipo de artritis que afecta a los niños y causa dolor en las articulaciones, hinchazón, sensación de calor, rigidez y pérdida de movimiento. La enfermedad empieza cuando el sistema inmunitario, que normalmente ayuda a combatir infecciones y a sanar cortadas y heridas, se vuelve hiperactivo y causa inflamación. El tratamiento depende del tipo de artritis idiopática juvenil y de la gravedad de los síntomas, pero, en general, incluye una combinación de medicamentos, terapia física y citas médicas con regularidad. Los tratamientos pueden ayudar a los niños con esta enfermedad a participar en diversas actividades. Hay muchas cosas que puede hacer en casa para ayudar a su niño a vivir con la enfermedad, como cuidar las articulaciones adoloridas, tener un equilibrio entre los momentos de descanso y el ejercicio, coordinar esfuerzos con la escuela y manejar el estrés.

• Publication year

  2022

• Venue

  Medicine - Programa de Formación Médica Continuada Acreditado

• Publication date

  2022-09-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.med.2022.08.004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

  2024cited by this paper
• Efficacy and safety of abatacept for systemic juvenile idiopathic arthritis: a systematic review.

  2024cited by this paper
• Juvenile idiopathic arthritis and its associated uveitis

  2023cited by this paper
• Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease

  2023cited by this paper
• Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe

  2023cited by this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

  2022cited by this paper
• Efficacy and safety of emapalumab in macrophage activation syndrome

  2022cited by this paper
• Growth and puberty in children with juvenile idiopathic arthritis

  2021cited by this paper
• Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches

  2021cited by this paper
• Signals and Mechanisms Regulating Monocyte and Macrophage Activation in the Pathogenesis of Juvenile Idiopathic Arthritis

  2021cited by this paper
• Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis

  2019cited by this paper
• Artritis idiopática juvenil: manejo y diagnóstico diferencial

  2019cited by this paper
• 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis

  2019cited by this paper
• Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus

  2018cited by this paper
• Treating juvenile idiopathic arthritis to target: recommendations of an international task force

  2018cited by this paper
• Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial

  2018cited by this paper
• Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

  2017cited by this paper
• Juvenile Idiopathic Arthritis

  2017cited by this paper
• A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis

  2017cited by this paper
• Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition

  2017cited by this paper
• [Recommendations for the use of methotrexate in patients with juvenile idiopathic arthritis].

  2016cited by this paper
• Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

  2016cited by this paper
• Immunogenetics of juvenile idiopathic arthritis: A comprehensive review.

  2015cited by this paper
• HLA Associations in a Cohort of Children With Juvenile Idiopathic Arthritis With and Without Uveitis.

  2015cited by this paper
• Prevalence and incidence of juvenile idiopathic arthritis: a systematic review.

  2014cited by this paper
• Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry

  2014cited by this paper
• Juvenile idiopathic arthritis.

  2012cited by this paper
• Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register

  2012cited by this paper
• Información en Español

  2011cited by this paper
• 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

  2011cited by this paper
• The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis.

  2011cited by this paper
• Cómo diagnosticamos y tratamos una enfermedad reumática: casos clínicos interactivos

  2010cited by this paper
• Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

  2009cited by this paper
• Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.

  2009cited by this paper
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• Artritis idiopática juvenil

  2009cited by this paper
• Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders

  2008cited by this paper
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

  2008cited by this paper
• Course, complications, and outcome of juvenile arthritis-related uveitis.

  2008cited by this paper
• High prevalence of temporomandibular joint arthritis at disease onset in children with juvenile idiopathic arthritis, as detected by magnetic resonance imaging but not by ultrasound.

  2008cited by this paper
• Juvenile idiopathic arthritis.

  2007cited by this paper
• Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study.

  2007cited by this paper
• Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature

  2006cited by this paper
• The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.

  2006cited by this paper
• Leflunomide or methotrexate for juvenile rheumatoid arthritis.

  2005cited by this paper
• Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis

  2004cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients.

  2001cited by this paper
• Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997.

  1998cited by this paper
• A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis.

  1986cited by this paper

• Clinical, Immunological and Inflammatory Characteristics among Mexican Children with Different Subtypes of Juvenile Idiopathic Arthritis: Exploring the Correlation between Anti-Cyclic Citrullinated Peptide (anti-CCP) and Rheumatoid Factor (RF)

  2024cites this paper
• Artritis idiopática juvenil con factor reumatoideo positivo y asociación con pancreatitis

  2021cites this paper
• Osteoporosis en las enfermedades autoinmunes sistmicas

  2008cites this paper